Pfizer
About
Pfizer Inc. (NYSE: PFE) is one of the world's largest pharmaceutical companies, with a broad portfolio spanning oncology, immunology, cardiology, and infectious disease, including legacy blockbusters like Eliquis for blood clots and Ibrance for breast cancer alongside newer acquisitions from its $43 billion purchase of Seagen's oncology pipeline. The company generated unprecedented revenue through its COVID-19 vaccine Comirnaty and antiviral Paxlovid, though the subsequent decline in pandemic-related sales has created a transition period as Pfizer works to replace that revenue through its oncology pivot and pipeline development. As an investment, Pfizer offers a compelling value proposition with its discounted valuation, high dividend yield, and the potential for significant growth from its newly acquired oncology assets, though execution on the Seagen integration remains the key catalyst to watch.
Pharmaceutical Stocks
Pfizer is a major pharmaceutical stock undergoing a strategic transformation, pivoting from its COVID-19 windfall toward becoming an oncology leader through the Seagen acquisition, while offering investors an attractive dividend yield and a deeply discounted valuation relative to its large-cap pharma peers.
Key Financials PFE
Price
$27.58
Change (1D)
+0.40%
Change (30D)
+10.76%
Change (60D)
+9.97%
Change (90D)
+4.35%
Change (180D)
+18.98%
Change (1Y)
+8.28%
Change (5Y)
-21.13%
P/E Ratio
8.54
EPS (TTM)
$3.23
52-Week Range
$20.92 — $27.94
50-Day MA
$25.84
Volume
36.95M
Data updated Feb 15 · Source: Twelve Data
